Bisphosphonates in the treatment of skeletal metastases

[31] The anti-tumour activity of bisphosphonates [J]. CANCER TREATMENT REVIEWS, 2002, 28 (06) : 305 - 319

[32] DOUBLE-BLIND CONTROLLED TRIAL OF ORAL CLODRONATE IN PATIENTS WITH BONE METASTASES FROM BREAST-CANCER [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (01) : 59 - 65

[33] PAVLAKIS N, 2002, COCHRANE DB SYST REV, V1

[34] Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (15) : 3219 - 3224

[35] Molecular mechanisms of action of bisphosphonates [J]. BONE, 1999, 24 (05) : 73S - 79S

[36] Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The zoledronic acid lung cancer and other solid tumors study group [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) : 3150 - 3157

[37] Rosen LS, 2001, CANCER J, V7, P377

[38] Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma - A randomized, double-blind, multicenter, comparative trial [J]. CANCER, 2003, 98 (08) : 1735 - 1744

[39] Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer [J]. BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7413): : 469 - 472

[40] Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases [J]. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2004, 62 (05) : 527 - 534

[31] The anti-tumour activity of bisphosphonates [J]. CANCER TREATMENT REVIEWS, 2002, 28 (06) : 305 - 319

[32] DOUBLE-BLIND CONTROLLED TRIAL OF ORAL CLODRONATE IN PATIENTS WITH BONE METASTASES FROM BREAST-CANCER [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (01) : 59 - 65

[33] PAVLAKIS N, 2002, COCHRANE DB SYST REV, V1

[34] Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (15) : 3219 - 3224

[35] Molecular mechanisms of action of bisphosphonates [J]. BONE, 1999, 24 (05) : 73S - 79S

[36] Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The zoledronic acid lung cancer and other solid tumors study group [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) : 3150 - 3157

[37] Rosen LS, 2001, CANCER J, V7, P377

[38] Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma - A randomized, double-blind, multicenter, comparative trial [J]. CANCER, 2003, 98 (08) : 1735 - 1744

[39] Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer [J]. BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7413): : 469 - 472

[40] Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases [J]. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2004, 62 (05) : 527 - 534